Log in

NASDAQ:AVROAvrobio Stock Price, Forecast & News

$16.50
-0.37 (-2.19 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.30
Now: $16.50
$17.42
50-Day Range
$16.03
MA: $18.44
$22.14
52-Week Range
$9.76
Now: $16.50
$29.32
Volume128,540 shs
Average Volume216,909 shs
Market Capitalization$594.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Avrobio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.87 per share

Profitability

Net Income$-72,960,000.00

Miscellaneous

Employees49
Market Cap$594.50 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$16.50
-0.37 (-2.19 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avrobio (NASDAQ:AVRO) Frequently Asked Questions

How has Avrobio's stock been impacted by COVID-19 (Coronavirus)?

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 8.4% and is now trading at $16.50.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Avrobio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avrobio
.

When is Avrobio's next earnings date?

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Avrobio
.

How were Avrobio's earnings last quarter?

Avrobio Inc (NASDAQ:AVRO) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04.
View Avrobio's earnings history
.

What price target have analysts set for AVRO?

7 brokerages have issued 1-year price targets for Avrobio's shares. Their forecasts range from $13.00 to $40.00. On average, they anticipate Avrobio's stock price to reach $31.80 in the next year. This suggests a possible upside of 92.7% from the stock's current price.
View analysts' price targets for Avrobio
.

Has Avrobio been receiving favorable news coverage?

News headlines about AVRO stock have trended very positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avrobio earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Avrobio
.

Are investors shorting Avrobio?

Avrobio saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 2,710,000 shares, an increase of 12.4% from the July 15th total of 2,410,000 shares. Based on an average trading volume of 335,800 shares, the short-interest ratio is currently 8.1 days. Currently, 9.3% of the company's shares are sold short.
View Avrobio's Current Options Chain
.

Who are some of Avrobio's key competitors?

What other stocks do shareholders of Avrobio own?

Who are Avrobio's key executives?

Avrobio's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
  • Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
  • Dr. Kim Warren, Head of Operations

When did Avrobio IPO?

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is Avrobio's stock symbol?

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Who are Avrobio's major shareholders?

Avrobio's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.31%), Emerald Mutual Fund Advisers Trust (2.08%), Swiss National Bank (0.17%), Alps Advisors Inc. (0.14%), Trexquant Investment LP (0.11%) and New York State Common Retirement Fund (0.08%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for Avrobio
.

Which institutional investors are buying Avrobio stock?

AVRO stock was bought by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Monarch Partners Asset Management LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and New York State Common Retirement Fund.
View insider buying and selling activity for Avrobio
.

How do I buy shares of Avrobio?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avrobio's stock price today?

One share of AVRO stock can currently be purchased for approximately $16.50.

How big of a company is Avrobio?

Avrobio has a market capitalization of $594.50 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

What is Avrobio's official website?

The official website for Avrobio is www.avrobio.com.

How can I contact Avrobio?

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.